News & Updates

In patients with idiopathic pulmonary fibrosis (IPF) aged >56 years, carrying the MUC5B minor allele translates to improved median transplant-free survival at 16 months, results of a retrospective study in Europe have shown.

The bivalent mRNA-1273.214 booster vaccine provides superior immunogenicity compared with the original COVID-19 mRNA-1273 vaccine in a phase III study, according to an expert who presented at ECCMID 2023.

Patients with severe COVID-19 requiring mechanical ventilation are 16 times more likely to develop ventricular tachycardia (V-tach) within 6 months following discharge compared with matched controls without severe infection in a Swedish case-control study presented at EHRA 2023.

In a functional assessment of post-COVID long-term sequelae, individuals suffering from long COVID (having at least one symptom of post-COVID-19 syndrome) had poorer quality of life (QoL) than those unaffected by the syndrome.

An “unfavourable” lifestyle appears to put individuals at increased risk of developing idiopathic pulmonary fibrosis, especially those with high genetic risk, according to a study.

A substantial proportion of transport drivers in Singapore had poor vaccine perception, were hesitant to receive the COVID-19 vaccine, and were unwilling to receive the third dose (booster shot) despite the high vaccination coverage in the city-state, a cross-sectional pilot study reports.

Treatment with valaciclovir leads to efficacious suppression of Epstein-Barr virus (EBV), having the potential to reduce the sputum inflammatory cell infiltrate, in patients with chronic obstructive pulmonary disease (COPD), according to data from the EViSCO study.